Suggested remit: To appraise the clinical and cost effectiveness of durvalumab within its marketing authorisation for induction and maintenance treatment of untreated advanced or recurrent endometrial cancer.
- Status:
- In progress
- Technology type:
- Medicine
- Decision:
- Selected
- Reason for decision:
- Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
- Process:
- STA Standard
- ID number:
- 6317
Project Team
- Project lead
- Jeremy Powell
Email enquiries
If you have any queries please email [email protected]
- External Assessment Group:
- BMJ Technology Assessment Group (BMJ-TAG), BMJ
Stakeholders
- Companies sponsors
- AstraZeneca (durvalumab, olaparib)
- Others
- Department of Health and Social Care
- NHS England
- Patient carer groups
- Peaches Womb Cancer Trust
- Professional groups
- Association of Cancer Physicians
- Cancer Research UK
- Royal College of Physicians
- Royal College of Radiologists
- Associated public health groups
- Public Health Wales
- UK Health Security Agency
- Comparator companies
- Accord (carboplatin, paclitaxel, cisplatin, doxorubicin) (confidentiality agreement not signed, not participating)
- Alliance Healthcare (cisplatin, cyclophosphamide, paclitaxel) (confidentiality agreement not signed, not participating)
- Bausch & Lomb (megestrol acetate) (confidentiality agreement not signed, not participating)
- Baxter Healthcare (cyclophosphamide) (confidentiality agreement not signed, not participating)
- Bristol Myers Squibb Pharmaceuticals (paclitaxel) (confidentiality agreement not signed, not participating)
- Consilient Health (carboplatin) (confidentiality agreement not signed, not participating)
- Fresenius Kabi (carboplatin, paclitaxel) (confidentiality agreement not signed, not participating)
- Hospira UK (carboplatin, paclitaxel) (confidentiality agreement not signed, not participating)
- Medac GmbH (doxorubicin) (confidentiality agreement not signed, not participating)
- Pfizer (carboplatin, paclitaxel, cisplatin,
- doxorubicin, medroxyprogesterone
- acetate) (confidentiality agreement not signed, not participating)
- Sandoz (cisplatin, cyclophosphamide) (confidentiality agreement not signed, not participating)
- Seacross Pharmaceuticals (paclitaxel, doxorubicin) (confidentiality agreement not signed, not participating)
- Teva UK (carboplatin, cisplatin, paclitaxel) (confidentiality agreement not signed, not participating)
- General commentators
- All Wales Therapeutics and Toxicology Centre
- Allied Health Professionals Federation
- Board of Community Health Councils in Wales
- British National Formulary
- Care Quality Commission
- Department of Health - Northern Ireland
- Healthcare Improvement Scotland
- Medicines and Healthcare products Regulatory Agency
- National Association of Primary Care
- National Pharmacy Association
- NHS Confederation
- Scottish Medicines Consortium
- Welsh Government
- NHS Wales Joint Commissioning Committee
- Relevant research groups
- Genomics England
- Institute of Cancer Research
- MRC Clinical Trials Unit
- National Institute for Health Research
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 25 July 2025 | Appeal |
| 12 June 2025 - 10 July 2025 | Final draft guidance |
| 26 June 2025 | NICE has been made aware of some inconsistencies regarding the appeal process for this appraisal. As a result, the publication of final guidance will be delayed and consultees will have the opportunity to submit appeals until 5pm Thursday 10 July. |
| 06 May 2025 | Committee meeting: 2 |
| 06 May 2025 | Declaration of interests |
| 26 March 2025 - 16 April 2025 | Draft guidance |
| 04 March 2025 | Committee meeting: 1 |
| 30 July 2024 | Invitation to participate |
| 25 March 2024 - 10 April 2024 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6317 |
| 24 January 2024 | Please note that following on from a request received from the company, the timelines for this appraisal have been revised and the appraisal is now anticipated to begin in late July 2024. These timings are based on a request from the company to reschedule the initial date set by NICE, in order to facilitate a suitably comprehensive and robust submission. |
| 08 December 2023 - 15 January 2024 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6317 |
| 08 December 2023 | In progress. Scoping commencing |
| 02 May 2023 | Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
For further information on our processes and methods, please see our CHTE processes and methods manual